<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008783</url>
  </required_header>
  <id_info>
    <org_study_id>Ak104-302</org_study_id>
    <nct_id>NCT05008783</nct_id>
  </id_info>
  <brief_title>A Study of AK104 in the First-line Treatment of Locally Advanced Unresectable or Metastatic G/GEJ Adenocarcinoma</brief_title>
  <official_title>A Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as First-line Treatment for Locally Advanced Unresectable or G/GEJ Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akeso</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akeso</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, Double-blind, Multicenter, phase III Clinical Study of Comparing the Efficacy&#xD;
      and Safety of AK104 Plus Oxaliplatin and Capecitabine (XELOX) Versus Placebo Plus XELOX as&#xD;
      First-line Treatment for locally advanced Unresectable or Metastatic Gastric Adenocarcinoma&#xD;
      or Gastroesophageal Junction Adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 16, 2021</start_date>
  <completion_date type="Anticipated">April 14, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 14, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PFS assessed by BIRC per RECIST v1.1 in the ITT population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (os)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>OS in the ITT population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>ORR is the proportion of subjects with CR or PR based on RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DCR is defined as the proportion of subjects with CR, PR, or SD, based on RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>DoR is defined as the duration from the first documentation of objective response to the first documented disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTR</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>TTR is defined as the time to response base on RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first assessed by investigator Per RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AE</measure>
    <time_frame>From the subject signs the ICF to 30 days (AE) and 90 days (SAE) after the last dose of study treatment or initiation of other anti-tumor therapy, whichever occurs first</time_frame>
    <description>Incidence and severity of adverse events (AEs) and serious adverse events (SAEs), and clinically significant abnormal laboratory results.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed concentrations of AK104</measure>
    <time_frame>From first dose of AK104 through the last dose of AK104, about average of 9 months.</time_frame>
    <description>The endpoints for assessment of PK of AK104 include serum concentrations of AK104 at different timepoints after AK104 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects who develop detectable anti-drug antibodies (ADAs)</measure>
    <time_frame>From first dose of AK104 through 30 days after last dose of AK104</time_frame>
    <description>The immunogenicity of AK104 will be assessed by summarizing the number of subjects who develop detectable antidrug antibodies (ADAs).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Gastric Adenocarcinoma</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>AK104 + Oxaliplatin + Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AK104 in combination with Oxaliplatin and Capecitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Oxaliplatin + Capecitabine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in combination with Oxaliplatin and Capecitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK104</intervention_name>
    <description>AK104 (administered on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, Q3W,up to 6 cycles) . Afterward, AK104 will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W)</description>
    <arm_group_label>AK104 + Oxaliplatin + Capecitabine</arm_group_label>
    <other_name>Oxaliplatin</other_name>
    <other_name>Capecitabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (administered on Day 1 of each cycle, Q3W)+Oxaliplatin (130 mg/m2 intravenous infusion for 2-6 hours on Day 1, Q3W,up to 6 cycles)+ Capecitabine(1000 mg/m2, p.o., Bid, Q3W,up to 6 cycles) . Afterward,Placebo will be used for maintenance treatment (administered on Day 1 of each cycle, Q3W)</description>
    <arm_group_label>Placebo + Oxaliplatin + Capecitabine</arm_group_label>
    <other_name>Oxaliplatin</other_name>
    <other_name>Capecitabine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects must meet all of the following inclusion criteria to be enrolled in the&#xD;
             study:&#xD;
&#xD;
               1. Ability to understand and voluntarily sign a written informed consent form (ICF),&#xD;
                  which must be signed before the specified study procedures required for the study&#xD;
                  are performed.&#xD;
&#xD;
               2. Males or females aged ≥ 18 to ≤ 75 years at the time of signing informed consent.&#xD;
&#xD;
               3. Histopathologically confirmed gastric adenocarcinoma or gastroesophageal junction&#xD;
                  (GEJ) adenocarcinoma.&#xD;
&#xD;
               4. Unresectable locally advanced or metastatic gastric adenocarcinoma or GEJ&#xD;
                  adenocarcinoma.&#xD;
&#xD;
               5. Subjects have not received prior systemic therapy for locally advanced or&#xD;
                  metastatic gastric adenocarcinoma or adenocarcinoma of the gastroesophageal&#xD;
                  junction. For subjects who have received prior neoadjuvant/adjuvant chemotherapy&#xD;
                  or chemoradiotherapy for curative intent, the time between disease progression&#xD;
                  and last treatment should be at least 6 months.&#xD;
&#xD;
               6. Subjects have at least one measurable tumor lesion per RECIST v1.1; lesions that&#xD;
                  received radiotherapy are not selected as target lesions, unless the lesion is&#xD;
                  the only measurable lesion and has unequivocal progression as judged by imaging,&#xD;
                  it can be considered as a target lesion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who meet any of the following criteria are not eligible to participate in&#xD;
             this study:&#xD;
&#xD;
               1. Subjects with known HER2-positive gastric or GEJ adenocarcinoma.&#xD;
&#xD;
               2. Histopathology or cytology confirmed other pathological types, such as squamous&#xD;
                  cell carcinoma, sarcoma, or undifferentiated carcinoma.&#xD;
&#xD;
               3. Subjects who received palliative local therapy for non-target lesions within 2&#xD;
                  weeks prior to the first dose; systemic nonspecific immunomodulatory therapy&#xD;
                  (e.g., interleukin, interferon, thymosin, etc.) within 2 weeks prior to the first&#xD;
                  dose; and Chinese herbal medicine or traditional Chinese medicinal products with&#xD;
                  anti-tumor indications within 2 weeks prior to the first dose.&#xD;
&#xD;
               4. Subjects who received any prior treatments targeting the mechanism of tumor&#xD;
                  immunity.&#xD;
&#xD;
               5. Medical history of gastrointestinal perforation or gastrointestinal fistula&#xD;
                  within 6 months prior to the first dose. If the perforation or fistula has been&#xD;
                  treated with resection or repair and the disease has recovered or resolved as&#xD;
                  judged by the Investigator, enrollment may be allowed.&#xD;
&#xD;
               6. Active or previously documented inflammatory bowel disease (e.g., Crohn's disease&#xD;
                  or ulcerative colitis).&#xD;
&#xD;
               7. Active malignancies within the past 3 years, with the exception of tumors in this&#xD;
                  study and cured local tumors, such as basal cell carcinoma of skin, squamous cell&#xD;
                  carcinoma of skin, superficial bladder cancer, carcinoma in situ of cervix,&#xD;
                  carcinoma in situ of breast, localized prostate cancer, etc.&#xD;
&#xD;
               8. Known active or untreated brain metastases, meningeal metastases, spinal cord&#xD;
                  compression, or leptomeningeal disease.&#xD;
&#xD;
               9. Presence of clinically symptomatic pleural effusion, pericardial effusion, or&#xD;
                  ascites requiring frequent drainage (≥ 1/month).&#xD;
&#xD;
              10. Active autoimmune disease requiring systemic treatment within 2 years prior to&#xD;
                  the start of study treatment, or autoimmune diseases that may relapse or require&#xD;
                  scheduled treatment as judged by the Investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiafu Ji, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lin Shen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zhifang Yao, MD</last_name>
    <phone>+86-0760-89873999</phone>
    <email>clinicaltrials@akesobio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100143</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jiafu Ji, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100143</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lin Shen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Zengqing Guo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mingzhu Huang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>20032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Tianshu Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ming Liu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yunnan Cancer Hospital</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650118</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lin Xie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhejiang University Medical College</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Nong Xu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 30, 2021</study_first_submitted>
  <study_first_submitted_qc>August 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

